Search

Selected EMA news

November 2024New medicines recommended for approval
Eltrombopag Viatris (eltrombopag) – generic
Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C (disease in which patients have low levels of blood platelets)

Alhemo (concizumab)
Prevention of bleeding in patients with hemophilia A…

Read more

EHA Research Conference 2025

Dates: March 17-20, 2025
Location: Málaga, Spain
Chairs: Alba Maiques Diaz, Ruud Delwel, Panagiotis Ntziachristos, Marcus Buschbeck, Mark Dawson, 
Özgen Deniz, Kimberly Stegmaier, and Nina Cabezas Wallscheid

Registration is now open

EHA is proud to announce the third edition of the EHA Research Conference, titled "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis".…

Read more

I4MDS consortium: advancing MDS treatment and understanding

The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.

Read more

Grants & abstract awards

EHA Travel GrantsThe call for travel grant applications will be open from January 1, 2025 until March 1, 2025 (23:59 CET). New: Grant applications have been integrated into the EHA2025 Abstract Submission form.

Read more

Meeting Program

EHA-SWG Secondary AML - April 2025



Read more

EHA-SFH joint membership

Save money and time by becoming a joint member of EHA and the Société Française d’Hématologie. We've joined forces with the Société Française d’Hématologie (SFH) to offer a special joint membership deal.

Read more

Nomination criteria

Nominations are open until 23:59 (CET) on January 15, 2025. Nominate now

General criteriaOur refreshed EHA Awards program is designed to recognize and encourage the extraordinary achievements of individuals across the field of hematology.

Read more